Australian TGA Stands By Pradaxa Approval
This article was originally published in PharmAsia News
Executive Summary
Australia's Therapeutic Goods Administration says that despite 280 associated deaths and 1,400 adverse reactions over the past five years, it has no plans to interfere with the marketing of Pradaxa (dabigatran) for preventing strokes.